drugset / Trial / NCT06273774
A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)
RandomizedSequentialTriple-blindTreatment
Summary
The goal of this study is to evaluate the safety and tolerability of elpipodect in participants with stable bipolar I disorder. There was no hypothesis testing in this study.
Timeline
- Start
- 2024-04-08
- Primary completion
- 2024-08-21
- Completion
- 2024-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-8189 | Small molecule | 24 mg | Oral |